Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

Next Previous
Trial Profile

A First-in-Human, Open-Label, Dose Escalation and Expansion Trial of BTX-9341 in Participants With Advanced and/or Metastatic Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BTX 9341 (Primary) ; Fulvestrant (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BioTheryX

Most Recent Events

  • 18 May 2026 Results(as of May 6, 2026 ) presented at BioTheryX media release.
  • 04 May 2026 According to a BioTheryX media release, data from the trial will be presented at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, taking place May 6 -8 in Berlin, Germany.
  • 18 Mar 2026 According to a BioTheryX media release, company announced that the first patient has been dosed in the dose expansion phase of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top